Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
1.550
-0.010 (-0.64%)
Apr 25, 2025, 11:27 AM EDT - Market open
Biodexa Pharmaceuticals Employees
Biodexa Pharmaceuticals had 13 employees as of December 31, 2024. The number of employees decreased by 8 or -38.10% compared to the previous year.
Employees
13
Change (1Y)
-8
Growth (1Y)
-38.10%
Revenue / Employee
n/a
Profits / Employee
-$551,714
Market Cap
3.97M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BDRX News
- 8 days ago - Notice of General Meeting - GlobeNewsWire
- 14 days ago - Preliminary Results for the Year Ended 31 December 2024 - GlobeNewsWire
- 5 weeks ago - With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - Accesswire
- 6 weeks ago - Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP - GlobeNewsWire
- 7 weeks ago - Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP - GlobeNewsWire
- 2 months ago - Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use - GlobeNewsWire
- 2 months ago - Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 - GlobeNewsWire
- 2 months ago - Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Accesswire